Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model

Johnny Peterson, Jason Comer, Wallace B. Baze, David M. Noffsinger, Autumn Wenglikowski, Kristin G. Walberg, Jason Hardcastle, Jennifer Pawlik, Kathryn Bush, Joanna Taormina, Scott Moen, John Thomas, Bagram M. Chatuev, Laurie Sower, Ashok Chopra, Lawrence R. Stanberry, Ritsuko Sawada, Wolfgang W. Scholz, Jagadish Sircar

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Dutch-belted and New Zealand White rabbits were passively immunized with AVP-21D9, a human monoclonal antibody to protective antigen (PA), at the time of Bacillus anthracis spore challenge using either nasal instillation or aerosol challenge techniques. AVP-21D9 (10 mg/kg) completely protected both rabbit strains against lethal infection with Bacillus anthracis Ames spores, regardless of the inoculation method. Further, all but one of the passively immunized animals (23/24) were completely resistant to rechallenge with spores by either respiratory challenge method at 5 weeks after primary challenge. Analysis of the sera at 5 weeks after primary challenge showed that residual human anti-PA levels decreased by 85 to 95%, but low titers of rabbit-specific anti-PA titers were also measured. Both sources of anti-PA could have contributed to protection from rechallenge. In a subsequent study, bacteriological and histopathology analyses revealed that B. anthracis disseminated to the bloodstream in some naive animals as early as 24 h postchallenge and increased in frequency with time. AVP-21D9 significantly reduced the dissemination of the bacteria to the bloodstream and to various organs following infection. Examination of tissue sections from infected control animals, stained with hematoxylin-eosin and the Gram stain, showed edema and/or hemorrhage in the lungs and the presence of bacteria in mediastinal lymph nodes, with necrosis and inflammation. Tissue sections from infected rabbits dosed with AVP-21D9 appeared comparable to corresponding tissues from uninfected animals despite lethal challenge with B. anthracis Ames spores. Concomitant treatment with AVP-21D9 at the time of challenge conferred complete protection in the rabbit inhalation anthrax model. Early treatment increased the efficacy progressively and in a dose-dependent manner. Thus, AVP-21D9 could offer an adjunct or alternative clinical treatment regimen against inhalation anthrax.

Original languageEnglish (US)
Pages (from-to)3414-3424
Number of pages11
JournalInfection and Immunity
Volume75
Issue number7
DOIs
StatePublished - Jul 2007

Fingerprint

Bacillus anthracis
Monoclonal Antibodies
Rabbits
Spores
Antigens
Lung
Bacteria
Hematoxylin
Eosine Yellowish-(YS)
Infection
Aerosols
Nose
AVP-21D9
Edema
Necrosis
Lymph Nodes
Hemorrhage
Inflammation
Serum

ASJC Scopus subject areas

  • Immunology

Cite this

Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model. / Peterson, Johnny; Comer, Jason; Baze, Wallace B.; Noffsinger, David M.; Wenglikowski, Autumn; Walberg, Kristin G.; Hardcastle, Jason; Pawlik, Jennifer; Bush, Kathryn; Taormina, Joanna; Moen, Scott; Thomas, John; Chatuev, Bagram M.; Sower, Laurie; Chopra, Ashok; Stanberry, Lawrence R.; Sawada, Ritsuko; Scholz, Wolfgang W.; Sircar, Jagadish.

In: Infection and Immunity, Vol. 75, No. 7, 07.2007, p. 3414-3424.

Research output: Contribution to journalArticle

Peterson, J, Comer, J, Baze, WB, Noffsinger, DM, Wenglikowski, A, Walberg, KG, Hardcastle, J, Pawlik, J, Bush, K, Taormina, J, Moen, S, Thomas, J, Chatuev, BM, Sower, L, Chopra, A, Stanberry, LR, Sawada, R, Scholz, WW & Sircar, J 2007, 'Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model', Infection and Immunity, vol. 75, no. 7, pp. 3414-3424. https://doi.org/10.1128/IAI.00352-07
Peterson, Johnny ; Comer, Jason ; Baze, Wallace B. ; Noffsinger, David M. ; Wenglikowski, Autumn ; Walberg, Kristin G. ; Hardcastle, Jason ; Pawlik, Jennifer ; Bush, Kathryn ; Taormina, Joanna ; Moen, Scott ; Thomas, John ; Chatuev, Bagram M. ; Sower, Laurie ; Chopra, Ashok ; Stanberry, Lawrence R. ; Sawada, Ritsuko ; Scholz, Wolfgang W. ; Sircar, Jagadish. / Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model. In: Infection and Immunity. 2007 ; Vol. 75, No. 7. pp. 3414-3424.
@article{dc4c68438c904eeb85358923b104a595,
title = "Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model",
abstract = "Dutch-belted and New Zealand White rabbits were passively immunized with AVP-21D9, a human monoclonal antibody to protective antigen (PA), at the time of Bacillus anthracis spore challenge using either nasal instillation or aerosol challenge techniques. AVP-21D9 (10 mg/kg) completely protected both rabbit strains against lethal infection with Bacillus anthracis Ames spores, regardless of the inoculation method. Further, all but one of the passively immunized animals (23/24) were completely resistant to rechallenge with spores by either respiratory challenge method at 5 weeks after primary challenge. Analysis of the sera at 5 weeks after primary challenge showed that residual human anti-PA levels decreased by 85 to 95{\%}, but low titers of rabbit-specific anti-PA titers were also measured. Both sources of anti-PA could have contributed to protection from rechallenge. In a subsequent study, bacteriological and histopathology analyses revealed that B. anthracis disseminated to the bloodstream in some naive animals as early as 24 h postchallenge and increased in frequency with time. AVP-21D9 significantly reduced the dissemination of the bacteria to the bloodstream and to various organs following infection. Examination of tissue sections from infected control animals, stained with hematoxylin-eosin and the Gram stain, showed edema and/or hemorrhage in the lungs and the presence of bacteria in mediastinal lymph nodes, with necrosis and inflammation. Tissue sections from infected rabbits dosed with AVP-21D9 appeared comparable to corresponding tissues from uninfected animals despite lethal challenge with B. anthracis Ames spores. Concomitant treatment with AVP-21D9 at the time of challenge conferred complete protection in the rabbit inhalation anthrax model. Early treatment increased the efficacy progressively and in a dose-dependent manner. Thus, AVP-21D9 could offer an adjunct or alternative clinical treatment regimen against inhalation anthrax.",
author = "Johnny Peterson and Jason Comer and Baze, {Wallace B.} and Noffsinger, {David M.} and Autumn Wenglikowski and Walberg, {Kristin G.} and Jason Hardcastle and Jennifer Pawlik and Kathryn Bush and Joanna Taormina and Scott Moen and John Thomas and Chatuev, {Bagram M.} and Laurie Sower and Ashok Chopra and Stanberry, {Lawrence R.} and Ritsuko Sawada and Scholz, {Wolfgang W.} and Jagadish Sircar",
year = "2007",
month = "7",
doi = "10.1128/IAI.00352-07",
language = "English (US)",
volume = "75",
pages = "3414--3424",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "7",

}

TY - JOUR

T1 - Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model

AU - Peterson, Johnny

AU - Comer, Jason

AU - Baze, Wallace B.

AU - Noffsinger, David M.

AU - Wenglikowski, Autumn

AU - Walberg, Kristin G.

AU - Hardcastle, Jason

AU - Pawlik, Jennifer

AU - Bush, Kathryn

AU - Taormina, Joanna

AU - Moen, Scott

AU - Thomas, John

AU - Chatuev, Bagram M.

AU - Sower, Laurie

AU - Chopra, Ashok

AU - Stanberry, Lawrence R.

AU - Sawada, Ritsuko

AU - Scholz, Wolfgang W.

AU - Sircar, Jagadish

PY - 2007/7

Y1 - 2007/7

N2 - Dutch-belted and New Zealand White rabbits were passively immunized with AVP-21D9, a human monoclonal antibody to protective antigen (PA), at the time of Bacillus anthracis spore challenge using either nasal instillation or aerosol challenge techniques. AVP-21D9 (10 mg/kg) completely protected both rabbit strains against lethal infection with Bacillus anthracis Ames spores, regardless of the inoculation method. Further, all but one of the passively immunized animals (23/24) were completely resistant to rechallenge with spores by either respiratory challenge method at 5 weeks after primary challenge. Analysis of the sera at 5 weeks after primary challenge showed that residual human anti-PA levels decreased by 85 to 95%, but low titers of rabbit-specific anti-PA titers were also measured. Both sources of anti-PA could have contributed to protection from rechallenge. In a subsequent study, bacteriological and histopathology analyses revealed that B. anthracis disseminated to the bloodstream in some naive animals as early as 24 h postchallenge and increased in frequency with time. AVP-21D9 significantly reduced the dissemination of the bacteria to the bloodstream and to various organs following infection. Examination of tissue sections from infected control animals, stained with hematoxylin-eosin and the Gram stain, showed edema and/or hemorrhage in the lungs and the presence of bacteria in mediastinal lymph nodes, with necrosis and inflammation. Tissue sections from infected rabbits dosed with AVP-21D9 appeared comparable to corresponding tissues from uninfected animals despite lethal challenge with B. anthracis Ames spores. Concomitant treatment with AVP-21D9 at the time of challenge conferred complete protection in the rabbit inhalation anthrax model. Early treatment increased the efficacy progressively and in a dose-dependent manner. Thus, AVP-21D9 could offer an adjunct or alternative clinical treatment regimen against inhalation anthrax.

AB - Dutch-belted and New Zealand White rabbits were passively immunized with AVP-21D9, a human monoclonal antibody to protective antigen (PA), at the time of Bacillus anthracis spore challenge using either nasal instillation or aerosol challenge techniques. AVP-21D9 (10 mg/kg) completely protected both rabbit strains against lethal infection with Bacillus anthracis Ames spores, regardless of the inoculation method. Further, all but one of the passively immunized animals (23/24) were completely resistant to rechallenge with spores by either respiratory challenge method at 5 weeks after primary challenge. Analysis of the sera at 5 weeks after primary challenge showed that residual human anti-PA levels decreased by 85 to 95%, but low titers of rabbit-specific anti-PA titers were also measured. Both sources of anti-PA could have contributed to protection from rechallenge. In a subsequent study, bacteriological and histopathology analyses revealed that B. anthracis disseminated to the bloodstream in some naive animals as early as 24 h postchallenge and increased in frequency with time. AVP-21D9 significantly reduced the dissemination of the bacteria to the bloodstream and to various organs following infection. Examination of tissue sections from infected control animals, stained with hematoxylin-eosin and the Gram stain, showed edema and/or hemorrhage in the lungs and the presence of bacteria in mediastinal lymph nodes, with necrosis and inflammation. Tissue sections from infected rabbits dosed with AVP-21D9 appeared comparable to corresponding tissues from uninfected animals despite lethal challenge with B. anthracis Ames spores. Concomitant treatment with AVP-21D9 at the time of challenge conferred complete protection in the rabbit inhalation anthrax model. Early treatment increased the efficacy progressively and in a dose-dependent manner. Thus, AVP-21D9 could offer an adjunct or alternative clinical treatment regimen against inhalation anthrax.

UR - http://www.scopus.com/inward/record.url?scp=34447258679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447258679&partnerID=8YFLogxK

U2 - 10.1128/IAI.00352-07

DO - 10.1128/IAI.00352-07

M3 - Article

VL - 75

SP - 3414

EP - 3424

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 7

ER -